Cleveland HeartLab Honored with Prestigious 2013 NorTech Innovation Award
Business Wire
CLEVELAND -- March 15, 2013
Cleveland HeartLab announced today that the company was recognized as a
recipient of the 2013 NorTech Innovation Awards. The award was received
yesterday by Cleveland HeartLab, President and CEO, Jake Orville at the annual
awards ceremony in Independence, Ohio.
Cleveland HeartLab was recognized for its work in the field of applied
biosciences for leadership in advanced cardiovascular testing. The company
offers a series of innovative clinical inflammation tests, including the
CardioMPO (Myeloperoxidase) test that focuses on the presence and activity of
vulnerable plaque in the blood. Subjects with increased MPO levels are at
increased risk for a heart attack. CHL’s breakthrough inflammation tests are
among the most effective methods to detect risk for potential heart attack and
are far more effective than basic cholesterol testing alone.
“Cleveland HeartLab is honored to receive a 2013 NorTech Innovation Award
along with such an impressive collection of leading companies that are on
track to make a difference locally and around the world,” said Jake Orville,
CHL President and CEO. “This award reflects our commitment to innovation and
our dedication to bringing scientifically proven and medically relevant tests
to market.”
Sponsored by NorTech and Crain’s Cleveland Business, the NorTech Innovation
Awards honor the region’s most innovative organizations that have either
demonstrated dramatic impact in a specific industry or market sector or have
the clear potential to do so in the near future.
The awards cover six distinct industries: advanced energy; advanced materials;
biosciences; flexible electronics; instrumentation, controls and electronics;
and water technologies. This year a total of seven companies were recognized,
including: Akron Surface Technologies, Inc.; CardioInsight / Nottingham Spirk;
Codonics, Inc.; NASA Glenn Research Center; quasar energy group; and SNS Nano
Fiber Technology, LLC.
“Our honorees are developing and commercializing exciting innovations that are
helping to revitalize Northeast Ohio’s economy,” NorTech President and CEO
Rebecca O. Bagley said. “These inspiring technologies are all vastly unique.
What they have in common is the potential to transform our region by creating
jobs, attracting capital and generating long-term, positive economic impact.
NorTech congratulates Cleveland HeartLab for receiving this prestigious
award.”
For detailed descriptions and short videos of all seven honorees and their
breakthrough technologies visit
www.nortech.org/regional-impact/success-stories/2013-innovation-awards.
The NorTech Innovation Awards ceremony highlighted Northeast Ohio as a place
of groundbreaking innovation that produces world-class technology every year.
A panel of distinguished judges, representing academia, venture capital,
private industry and economic development, selected this year’s NorTech
Innovation Awards winners from a number of high-quality nominations from
entrepreneurs, companies, research institutions and universities.
Judges included: Shauna Brummet, Ph.D., President & CEO, BioHio Research Park;
Peter Buca, Vice President of Technology & Innovation, Parker Hannifin
Corporation; Dennis Cocco, Co-Director, GLIDE; Andy Conti, Director of
External Innovation, Avery Dennison; Ajay Mahajan, Ph.D., Associate Dean for
Research & Professor of Mechanical Engineering, The University of Akron; Grant
McGimpsey, Ph.D., Vice President for Research and Sponsored Programs, Kent
State University; and Jay Schabel, CEO, RES Polyflow.
NorTech has presented the Innovation Awards since 2000. The 2013 NorTech
Innovation Awards were presented by NorTech, Crain's Cleveland Business and
Kent State University, and sponsored by Cleveland Public Power, Keystone
Compliance and Fay Sharpe LLP.
About Cleveland HeartLab:
Cleveland HeartLab Inc. is a specialty clinical laboratory and cardiovascular
disease management company focused on offering a robust menu of propriety
diagnostic tests based on unique molecular biomarkers. CHL operates a
CLIA-certified and CAP-accredited clinical laboratory. It has developed a
panel of tests that thousands of practitioners use in the management and
prevention of heart disease. CHL also runs a research and development
laboratory where next-generation cardiovascular disease biomarkers are being
developed for use through CHL’s clinical laboratory. This valuable pipeline of
tests is part of an exclusive intellectual property portfolio that targets
large, under-addressed markets. For more information about Cleveland HeartLab,
please visit the company’s website at clevelandheartlab.com.
About NorTech:
NorTech, a technology-based economic development organization, is working to
revitalize Northeast Ohio’s economy by accelerating the growth of regional
innovation clusters in the advanced energy, flexible electronics and water
technologies industries. NorTech engages small, large and midsize companies
and universities for business, funding and research opportunities that create
jobs, attract capital, and have a long-term, positive economic impact for the
region.
Contact:
The Luminis Group, Ltd. for Cleveland HeartLab Inc.
Rod Hise, 608-807-4607
rod@luminisgroupltd.com